ROCKAWAY, N.J., July 23, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will report financial results for the second quarter ended June 30, 2025, after the close of the market on Wednesday, August 6, 2025.
Management will host a webinar at 4:30 PM EDT to review the financial results and answer questions. Investors can access the webinar using the details below:
Wednesday, August 6, 4:30 PM EDT
Dial-In: (646) 931-3860
Webinar ID: 843 8084 9004
Passcode: 049555
Registration Link: Click here to participate and ask questions on the call.
About electroCore, Inc.
electroCore, Inc. is a commercial stage bioelectronic technology company whose mission is to improve health and quality of life through innovative non-invasive bioelectronic technologies. The Company’s two leading prescription products to treat chronic pain syndromes through non-invasive neuromodulation technology are gammaCore non-invasive vagus nerve stimulation (nVNS) and Quell neurostimulator. Additionally, the company commercializes its Truvaga products, handheld, and personal use nVNS products utilizing bioelectronic technologies, to promote general wellness and human performance.
For more information, visit www.electrocore.com.
Contact
ECOR Investor Relations
(973) 302-9253
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$5.37 |
| Daily Change: | 0.13 2.39 |
| Daily Volume: | 95,041 |
| Market Cap: | US$40.080M |
August 06, 2025 | |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
